NASDAQ: CTKB · Medical Devices
Cytek Biosciences (CTKB) fair value: undervalued or overvalued?
As of 3 Oct 2026, Faircurve's model values Cytek Biosciences (CTKB) at $7.27 a share. The stock last closed at $5.87, which puts the model's fair value 23.9% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 2 Oct 2026. Cytek Biosciences, Inc.
Faircurve Insights · 3 Oct 2026
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings.
Faircurve's model on 3 Oct 2026 gave a fair value of $7.27 a share, the midpoint of 2,000 simulations. This was a move of +12.4% from the previous run on 26 Sep 2026, which gave $6.47. The calibrated range over 63 trading days was $6.07 to $8.81, built from the fair value. This method held the price 60% of the time at this horizon, and the model's evidence grade was Medium.
The overall quality score was 56 out of 100, against comparable companies. These comparable companies are Integra LifeSciences Holdings Corporation (IART), Enovis Corporation (ENOV), Artivion, Inc. (AORT), Tandem Diabetes Care, Inc. (TNDM), and UFP Technologies, Inc. (UFPT). The median size of moves around the last 8 earnings reports, ignoring direction, was 8.4%.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give CTKB?
The calibrated range for CTKB over 63 trading days is $6.07 to $8.81. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The price is below this range. For names with fair value 15 to 30% above price, the calibrated range has held the price 50% of the time over 63 trading days, and 48% ended below it; the typical move was +3.7%.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $6.27 to $8.33. In 90% of the simulations the fair value came out above the price the model ran on.
How does CTKB score on business quality?
Cytek Biosciences's overall quality score is 56 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 45 | -16.3%ROIC | -42.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 85 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 41 | 0.5%Revenue growth, trailing | 3.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 70 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 32 | 1.75xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 71 | 4.5 ptsEBITDA margin downside volatility, 5y | 25.1 pts |
How does CTKB compare with similar companies?
The companies in medical devices closest to Cytek Biosciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AHCO AdaptHealth Corp. | $5.60 | $5.55 | -0.9% | Low evidence grade |
| IART Integra LifeSciences Holdings Corporation | $12.68 | $15.96 | +25.9% | Undervalued |
| ENOV Enovis Corporation | $17.77 | $23.09 | +29.9% | Undervalued |
| AORT Artivion, Inc. | $22.31 | $26.81 | +20.2% | Undervalued |
| TNDM Tandem Diabetes Care, Inc. | $16.50 | $20.57 | +24.7% | Undervalued |
| CNMD CONMED Corporation | $46.32 | $57.63 | +24.4% | Low evidence grade |
| INSP Inspire Medical Systems, Inc. | $69.97 | $70.18 | +0.3% | Low evidence grade |
| UFPT UFP Technologies, Inc. | $300.70 | $278.76 | -7.3% | Fairly valued |
When does CTKB report earnings, and how has the stock reacted?
Cytek Biosciences's next earnings report is scheduled for 4 Nov 2026. Companies can move their dates.
How CTKB moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 8.4%.
| Report date | Two session move |
|---|---|
| 5 Aug 2026 | -2.8% |
| 7 May 2026 | -6.7% |
| 26 Feb 2026 | +2.5% |
| 5 Nov 2025 | +16.1% |
| 6 Aug 2025 | +5.9% |
| 8 May 2025 | -17.9% |
| 27 Feb 2025 | -10.2% |
| 5 Nov 2024 | +42.3% |
Cytek Biosciences at a glance
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings.
- Market value
- $758M
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $220M
- Consensus revenue growth, next fiscal year
- +3.9%
- Analysts with estimates
- 1
- Beta to the US market
- 0.77
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Cytek Biosciences on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for CTKB was $6.47. As of 3 Oct 2026 it is $7.27, a change of +12.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Cytek Biosciences's valuation
Is Cytek Biosciences stock undervalued or overvalued?
On Faircurve's model, CTKB reads as Undervalued as of 3 Oct 2026. The model's fair value is $7.27 a share against a last close of $5.87, a gap of +23.9%.
What is CTKB's fair value?
$7.27 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $6.27 to $8.33.
What price range does the model give CTKB?
$6.07 to $8.81 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does Cytek Biosciences report earnings next?
The next report is scheduled for 4 Nov 2026. Companies can move their dates.
How much has CTKB moved on past earnings reports?
Across its last 8 reports the median two session move was 8.4%, ignoring direction. The largest was +42.3% around the report of 5 Nov 2024.
How confident is the model in this valuation?
The model's evidence grade for CTKB is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.